Back to search results

NeuroFLiPP: Neuroinflammation in Fatty Liver Disease

This study is looking at how fatty liver disease might be connected to brain inflammation, which could play a role in Alzheimer's disease. Researchers will use special scans called PET scans (Positron Emission Tomography) with two different tracers, 18F-DPA-714 and 18F-FDG, to see how they compare in detecting brain activity. You might be able to join if you are 18 or older and are having a liver biopsy for fatty liver disease, as part of another study for a severe form of fatty liver disease (MASH), or before weight-loss surgery. The main goal is to compare the results of the two types of PET scans after three months. The current status of this study is unclear, and it plans to enroll 12 participants.

Study design
This is an interventional study, meaning participants will receive specific interventions. It plans to enroll 12 participants.
What's involved
Participants will undergo PET scans using 18F-DPA-714 and 18F-FDG. The primary endpoint is measured at 3 months.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at 3 months, indicating a follow-up period of at least that long.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06453915

NeuroFLiPP: Parametric PET of Neuroinflammation in Fatty Liver Disease

Recruiting
EARLY_PHASE1Ages 18+Interventional
University of California, Davis
~12 participants
Updated 2026-08-18 on ClinicalTrials.gov
What's tested:18F-DPA-71418F-FDG

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
results of 18F-FDG scans compared with results of DPA-714 scans
Measured over 3 months

Conditions

Positron Emission Tomography

Explore related trials

Nonalcoholic Fatty Liver Disease

NCT06453915

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • UC Davis EXPLORER Molecular Imaging Center

    Sacramento, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Guobao Wang, PhD · PRINCIPAL_INVESTIGATOR · UC Davis Health Department of Radiology

Who to contact

Dana Little, MS
[email protected]
916-734-7749
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants \>=18 years age
Participants who have or have planned a liver biopsy as:
standard of care for fatty liver disease with risk factors for metabolic dysfunction-associated steatohepatitis (MASH), or
as part of another Clinical Trials study for MASH, or
standard of care prior to undergoing bariatric surgery
Liver biopsy needs to be within 6 months of planned study-related imaging
Ability to provide informed consent.

Exclusion

History of alcohol abuse, chronic hepatitis B or C, or other chronic liver disease other than non-alcoholic fatty liver disease.
Uncontrolled claustrophobia
Body weight \>225 kg due to limitations of the scanner bed
Pregnant or breast-feeding (due to risks of ionizing radiation; urine pregnancy test will be administered prior to start of each PET/CT session for all participants between 18 to 60 years old who are able to get pregnant, unless documented hysterectomy is available)
Concurrent or prior enrollment in a separate research study involving a PET scan performed within the last 12 months for research purposes only.
Prisoners
Any comorbidity that, in the opinion of the investigator, could compromise protocol objectives.
Pre-existing neurodegenerative disorders and dementia
Significant history of major skull concussion or repetitive head trauma
Currently on anticoagulant therapy
Metal implants (e.g., pacemaker) or claustrophobia that would preclude MRI scans

What this trial measures

  • results of 18F-FDG scans compared with results of DPA-714 scans3 months

    validate the 18F-FDG method for assessing neuroinflammation in MASLD/MASH using 18F-DPA-714 as the reference